Cipher Pharmaceuticals Inc (TSE:CPH) (NASDAQ:CPHR) – Investment analysts at Cormark increased their FY2017 earnings estimates for Cipher Pharmaceuticals in a report issued on Monday. Cormark analyst D. Novak now expects that the company will earn $0.49 per share for the year, up from their prior estimate of $0.47.

CPH has been the topic of several other research reports. Bloom Burton downgraded Cipher Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Monday, August 14th. TD Securities lifted their price target on Cipher Pharmaceuticals from C$5.50 to C$6.50 in a research note on Monday, August 14th.

WARNING: “Cormark Equities Analysts Increase Earnings Estimates for Cipher Pharmaceuticals Inc (CPH)” was posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this report on another publication, it was illegally stolen and republished in violation of United States & international copyright law. The correct version of this report can be accessed at https://www.thecerbatgem.com/2017/11/08/cormark-equities-analysts-increase-earnings-estimates-for-cipher-pharmaceuticals-inc-cph.html.

Shares of Cipher Pharmaceuticals (TSE CPH) opened at C$4.75 on Tuesday. Cipher Pharmaceuticals has a 12 month low of C$3.50 and a 12 month high of C$5.75.

About Cipher Pharmaceuticals

Cipher Pharmaceuticals Inc, together with its subsidiaries, operates as a specialty pharmaceutical dermatology company in South America, Canada, and the United States. It offers CIP-ISOTRETINOIN, a formulation of the active ingredient isotretinoin for use in the treatment of severe acne; CIP-FENOFIBRATE, a formulation of the active ingredient fenofibrate used for the treatment of hyperlipidemia, a cholesterol disorder; and CIP-TRAMADOL ER, a formulation of the active ingredient tramadol for the management of moderate to moderately severe pain.

Receive News & Stock Ratings for Cipher Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cipher Pharmaceuticals Inc and related stocks with our FREE daily email newsletter.